The role of immunosuppressive treatment in inflammatory cardiomyopathy is still controversial. Nevertheless, it is recommended in patients with eosinophilic myocarditis, granulomatous myocarditis, giant-cell myocarditis and lymphocytic myocarditis associated with connective tissue diseases or with rejection of a transplanted heart. There is growing evidence that some patients with idiopathic active myocarditis and cardiac dysfunction may benefit from immunosuppression. In the present review we define, through analysis of recent reports and the results of our own studies, the biological markers of candidates for immunosuppression. (C) 2002 The European Society of Cardiology.
Immunosuppressive therapy in inflammatory cardiomyopathy / Frustaci, Andrea; M., Pieroni; Chimenti, Cristina. - In: EUROPEAN HEART JOURNAL SUPPLEMENTS. - ISSN 1520-765X. - STAMPA. - 4:I(2002), pp. I69-I72. (Intervento presentato al convegno International Symposium on New Aspects in Inflammatory Cardiomyopathy tenutosi a BERLIN, GERMANY nel JAN 18-20, 2002) [10.1016/s1520-765x(02)90114-8].
Immunosuppressive therapy in inflammatory cardiomyopathy
FRUSTACI, ANDREA;CHIMENTI, CRISTINA
2002
Abstract
The role of immunosuppressive treatment in inflammatory cardiomyopathy is still controversial. Nevertheless, it is recommended in patients with eosinophilic myocarditis, granulomatous myocarditis, giant-cell myocarditis and lymphocytic myocarditis associated with connective tissue diseases or with rejection of a transplanted heart. There is growing evidence that some patients with idiopathic active myocarditis and cardiac dysfunction may benefit from immunosuppression. In the present review we define, through analysis of recent reports and the results of our own studies, the biological markers of candidates for immunosuppression. (C) 2002 The European Society of Cardiology.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
